CeriBell (NASDAQ:CBLL - Get Free Report)'s share price rose 9.1% during trading on Tuesday . The stock traded as high as $22.91 and last traded at $22.95. Approximately 113,825 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 210,938 shares. The stock had previously closed at $21.04.

Several research firms have recently weighed in on CBLL. Canaccord Genuity Group assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set a "buy" rating and a $30.00 target price for the company. Canaccord Genuity Group raised their price target on CeriBell from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Monday, December 9th. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an "overweight" rating and a $32.00 price objective for the company. William Blair started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an "outperform" rating for the company. Finally, TD Cowen increased their price objective on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell currently has an average rating of "Buy" and a consensus price target of $32.60.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. As a group, equities analysts expect that CeriBell will post -2.46 earnings per share for the current year.

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography ("EEG") platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider CeriBell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.

While CeriBell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.